CD&R Secures $3.1B Debt Package for Option Care Health Acquisition

Clayton, Dubilier & Rice locked $3.1 billion in committed debt financing from a syndicate of Wall Street banks for its acquisition of Option Care Health alongside McKesson Corp. The facility closed within three weeks of deal announcement, a pace that signals institutional appetite for scaled healthcare infrastructure assets even as broader private equity transaction volume collapsed 65% year-over-year through October.

Option Care Health operates the largest independent home and alternate site infusion services platform in the United States, managing approximately 90,000 active patients and 185 infusion pharmacy locations. McKesson, which held a 71% ownership stake, is exiting alongside CD&R's entry at an undisclosed enterprise valuation. The debt structure includes a term loan B and a revolver, sized to accommodate both acquisition consideration and ongoing working capital requirements for a business generating roughly $4.2 billion in annual revenue. Banks leading the commitment include the usual healthcare lending desks—exact names withheld pending syndication close—but the speed of full underwriting suggests minimal price discovery friction.

The financing lands in a month where private equity deal value globally fell to multi-year lows, yet healthcare assets continue drawing committed capital. CD&R's willingness to lever a healthcare services business at this scale, in this rate environment, reflects two calculations: first, that home infusion is a structurally growing category as site-of-care shifts accelerate, and second, that institutional lenders remain willing to price large healthcare facilities inside of L+450 for sponsors with operational track records. The firm has been building a healthcare vertical for eight years, with prior investments in Envision Healthcare and athenahealth providing both sector knowledge and cautionary tales about regulatory exposure.

What makes this financing notable is not the size but the certainty. In an environment where many sponsors are bridging deals with delayed syndication or accepting tighter covenants, CD&R secured full commitment upfront. That suggests the banks modeled stable EBITDA through a recession—home infusion volumes are acuity-driven, not discretionary—and likely received sponsor equity contribution north of 40%. The absence of flexed pricing or delayed takeout also implies the deal was marketed to a narrow group of relationship lenders rather than broadly syndicated, a pattern emerging among top-tier sponsors who value execution speed over marginal cost savings.

Allocators should watch for syndication details within 30 days, particularly any pricing flex or covenant structure changes as the facility moves from commitment to funded tranches. If the deal syndicates cleanly at initial terms, expect similar home healthcare and healthcare IT assets to come to market with aggressive timelines into Q1 2025. Separately, McKesson's decision to exit despite secular tailwinds in home infusion suggests either portfolio rationalization ahead of capital deployment elsewhere or a view that CD&R's operational playbook—likely involving SG&A compression and payer contract renegotiation—will drive returns that a strategic holder cannot.

The deal closed in a week when EQT and other large sponsors also announced healthcare commitments, confirming that capital is sector-rotating rather than broadly withdrawing. CD&R now controls the largest independent infusion platform at a moment when hospital systems are offloading complex care to lower-cost sites, and payers are reimbursing home administration at rates that make the unit economics durable even under Medicare Advantage pressure.